Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
Journal for ImmunoTherapy of Cancer · 2023-03 · 11 (3) · e006243
DOI: 10.1136/jitc-2022-006243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.03.2023. Verfasst von Gang Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Xiangya Hospital Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Brain Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases of Chin, Advanced Lung Cancer Research Fund for targeted therapy in China, Beijing Xisike Clinical Oncology and Research Foundation.
Abstract (Originalsprache)
Background
Previous studies found that lung adenocarcinomas (LUAD) with EGFR-positive and ALK-positive were less responsive to immunotherapy, which may be associated with a suppressive tumor immune microenvironment (TIME). Given the discordance in the TIME between primary lung cancer and brain metastasis, it is urgent to explore the TIME in patients with EGFR/ALK-positive LUAD with brain metastases (BMs).
Methods
The transcriptome feature of formalin-fixed and paraffin-embedded samples of BMs and paired primary LUAD from 70 patients with LUAD BMs was illustrated by RNA-sequencing. Six of them were available for paired sample analysis. Then, after excluding 3 co-occurring patients, we divided 67 BMs patients into 41 EGFR/ALK-positive and 26 EGFR/ALK-negative patients. The differences in immune profiling between the two groups were analyzed from three dimensions: TIME, T-cell receptor repertoire, and immunohistochemistry. Finally, the survival data of 55 patients were collected.
Results
Compared with primary LUAD, BMs present an immunosuppressed TIME, manifested as: inhibition of immune-related pathways; low expression of immune checkpoint; decreased infiltration of CD8+T cells and cytotoxic lymphocyte; increased proportion of suppressive M2 macrophages. In different subgroups based on EGFR/ALK gene variation status, both EGFR-positive and ALK-positive tumors present a relatively immunosuppressive microenvironment, but the heterogeneity of tumor microenvironment may undergo different mechanisms. EGFR-positive BMs showed decreased CD8+T cells and increased regulatory T cells (Treg) cells, while ALK-positive BMs showed decreased CD8+T cells and increased M2 macrophages. Moreover, in the TCGA-LUAD cohort, EGFR-positive tumors showed reduced CD8+T cell infiltrations (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Xiangya Hospital Central South University, Changsha, Hunan, China.
- Geneplus-Beijing, Beijing, China.
- Institute of Microbiology, Chinese Academy of Sciences, State Key Laboratory of Microbial Resources, Beijing, China.
- GenePlus-Shenzhen Clinical Laboratory, Shenzhen, China.
- Department of Neurosurgery, Xiangya Hospital Central South University, Changsha, Hunan, China.
- Department of Pathology, Xiangya Hospital Central South University, Changsha, Hunan, China.
ORCID-Profile: Rongrong Zhou
Förderung
- National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases of Chin
- Advanced Lung Cancer Research Fund for targeted therapy in China
- Beijing Xisike Clinical Oncology and Research Foundation
Zitieren
APA
Xiao, G., Li, L., Tanzhu, G., Liu, Z., Gao, X., Wan, X., Xiao, D., Chen, L., Xia, X., & Zhou, R. (2023). Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. Journal for ImmunoTherapy of Cancer, 11(3), e006243. https://doi.org/10.1136/jitc-2022-006243
Vancouver
Xiao G, Li L, Tanzhu G, Liu Z, Gao X, Wan X, et al. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. 2023;11(3):e006243. doi:10.1136/jitc-2022-006243
BibTeX
@article{Xiao2023,
author = {Xiao, Gang and Li, Lifeng and Tanzhu, Guilong and Liu, Zhiyuan and Gao, Xuan and Wan, Xin and Xiao, Desheng and Chen, Liu and Xia, Xuefeng and Zhou, Rongrong},
title = {Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {3},
pages = {e006243},
doi = {10.1136/jitc-2022-006243}
}
EUVIMED